Reuters logo
BRIEF-EMA grants Alnylam accelerated assessment of rare disease drug
2017年11月13日 / 下午12点44分 / 8 天前

BRIEF-EMA grants Alnylam accelerated assessment of rare disease drug

Nov 13 (Reuters) - Alnylam Pharmaceuticals Inc

* European Medicines Agency (EMA) grants Alnylam accelerated assessment of patisiran for patients with hereditary attr (hattr) amyloidosis

* Alnylam Pharmaceuticals Inc - ‍company on track to submit marketing authorization application (maa) and new drug application (nda) at year-end 2017​

* Alnylam Pharmaceuticals Inc - ‍alnylam intends to file a marketing authorization application (maa) in european union (eu) at year-end 2017​

* Alnylam Pharmaceuticals Inc - ‍alnylam plans to file a new drug application for patisiran in united states by end of 2017​

* Alnylam Pharmaceuticals Inc - ‍pending regulatory approvals, alnylam will commercialize patisiran in u.s., canada and western europe​

* Alnylam Pharmaceuticals Inc - ‍pending regulatory approvals sanofi genzyme commercializing product in rest of world​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below